Projekt · Dnr 2017-03467 · Källa: Vinnova

E!11481, E-OxidoCurin, HDXperts AB

Koordinator
HDxperts AB
Projekttid
2017-10-01 till 2021-12-31 (avslutat)
Beviljat bidrag
4 888 259 SEK
Diarienummer
2017-03467

Beskrivning

All the goals of the project were fulfilled. 1) A new water-soluble lead compound LCTA2940 was synthesized. 2) The TrxR1 target was validated, and the mechanism of interaction and ROS dependent action was elucidated. 3) Using proteomics, we identified additional targets. 4) In vivo LCTA2940 effectively suppressed the growth of xenograft tumors without side effects. 5) Bioinformatics analysis of sensitivity profiles of 27 cancer cell lines identified biomarkers for compounds efficacy and possible toxicity. Our novel anti-cancer compound LCTA2940 has an exceptional set of pharmacological properties such as significant tumor suppression in animal models in vivo, along with no damage in DNA and little effect on normal cells. The mechanism of action of LCTA2940 involves the induction of ROS via targeting TrxR1. LCTA2940 has increased efficiency in hypoxic cells, which are the most aggressive types of cancer. We also have shown that the compound LCTA2940 kills cancer stem cells, which reduces the risk of recurrence and reduces the likelihood of treatment resistance.

Öppna hos Vinnova

Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.

Liknande

  1. E!113292, nOVAB, Göteborgs Universitet

    Göteborgs universitet · 2019-10-01 · 2 217 459 SEK · Projekt

    We recently discovered a specific epitope (referred to herein as “t334”-the target) of a monoclonal antibody that blocks a tumour cell-specific target, leading to cell death and reduced tumour growth via a novel cancer pathway. This target belongs to a family of transmembrane serine/threonine tyrosi…

  2. Development and clinical microdose study of an albumin-binding PET imaging agent for blood flow measurement

    Affibody AB · 2010-11-08 · 5 000 000 SEK · Projekt

    <p>The goal of the project was to develop and produce a novel radiotracer for imaging of blood flow/permeability in tumors and to investigate its suitability in first clinical trials. Peptide synthesis yielded functional and stable ABY-028. In vivo studies with [68Ga]ABY-028 proved the suitability f…

  3. Innovative Strategy for Targeted Delivery of Precision Medicine Drugs (INSPIRE)

    Uppsala Therapeutics AB · 2021-05-01 · 1 918 560 SEK · Projekt

    The aim of the project was to synthesize chemically modified oligonucleotides that are sensitive to stimuli like alkaline phosphatase and esterase. We have developed esterase-sensitive drug-siRNA conjugates and alkaline-sensitive chemically modified siRNA and DisiRNA. All our siRNAs are functional i…

  4. Preklinisk utveckling av MTHFD2 hämmare för behandling av cancer

    One-carbon Therapeutics AB · 2022-04-01 · 3 000 000 SEK · Projekt

    The overall goal for the project was to progress the development of novel cancer therapy from the preclinical to the clinical stage and enable first-in-human clinical trials of MTHFD1/2 inhibitors. The project has successfully executed work packages and delivered milestones as described in the appli…

  5. OssiGel: the formation of human mini-bones as personalized drug-testing platform

    Lunds universitet · 2023-11-01 · 970 000 SEK · Projekt

    Many cancers emerge or ultimately develop our in bones, including acute myeloid leukemia. Current treatments show poor success rates, calling for more relevant models. To address this, OssiGel is proposed as a technology for generating human mini-bones (ossicles) using patient cells, enabling better…